ALK and non-small cell lung carcinoma: Nowadays, the development of ALK inhibitors (ALK-i) has changed the treatment landscape of cancer patients with ALK alterations, as demonstrated by the dramatic and often prolonged responses to treatment achieved in patients affected by metastatic NSCLC [7].